Cargando…
Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for the prevention of cardiovascular (CV) events. However, the clinical significance of circulating PCSK9 is unclear in hemodialysis (HD) patients. A total of 353 HD patients were prospectively enrolled from June 2016 to...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019341/ https://www.ncbi.nlm.nih.gov/pubmed/31963408 http://dx.doi.org/10.3390/jcm9010244 |
_version_ | 1783497502655250432 |
---|---|
author | Hwang, Hyeon Seok Kim, Jin Sug Kim, Yang Gyun Lee, So-Young Ahn, Shin Young Lee, Hong Joo Lee, Dong-Young Lee, Sang Ho Moon, Ju Young Jeong, Kyung Hwan |
author_facet | Hwang, Hyeon Seok Kim, Jin Sug Kim, Yang Gyun Lee, So-Young Ahn, Shin Young Lee, Hong Joo Lee, Dong-Young Lee, Sang Ho Moon, Ju Young Jeong, Kyung Hwan |
author_sort | Hwang, Hyeon Seok |
collection | PubMed |
description | Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for the prevention of cardiovascular (CV) events. However, the clinical significance of circulating PCSK9 is unclear in hemodialysis (HD) patients. A total of 353 HD patients were prospectively enrolled from June 2016 to August 2019 in a K-cohort. Plasma PCSK9 level was measured at the time of study enrollment. The primary endpoint was defined as a composite of CV event and death. Plasma PCSK9 level was positively correlated with total cholesterol level in patients with statin treatment. Multivariate linear regression analysis revealed that baseline serum glucose, albumin, total cholesterol, and statin treatment were independent determinants of circulating PCSK9 levels. Cumulative rates of composite and CV events were significantly higher in patients with tertile 3 PCSK9 (p = 0.017 and p = 0.010, respectively). In multivariate Cox-regression analysis, PCSK9 tertile 3 was associated with a 1.97-fold risk of composite events (95% CI, 1.13–3.45), and it was associated with a 2.31-fold risk of CV events (95% CI, 1.17–4.59). In conclusion, a higher circulating PCSK9 level was independently associated with incident CV events and death in HD patients. These results suggest the importance of future studies regarding the effect of PCSK9 inhibition. |
format | Online Article Text |
id | pubmed-7019341 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70193412020-03-09 Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients Hwang, Hyeon Seok Kim, Jin Sug Kim, Yang Gyun Lee, So-Young Ahn, Shin Young Lee, Hong Joo Lee, Dong-Young Lee, Sang Ho Moon, Ju Young Jeong, Kyung Hwan J Clin Med Article Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for the prevention of cardiovascular (CV) events. However, the clinical significance of circulating PCSK9 is unclear in hemodialysis (HD) patients. A total of 353 HD patients were prospectively enrolled from June 2016 to August 2019 in a K-cohort. Plasma PCSK9 level was measured at the time of study enrollment. The primary endpoint was defined as a composite of CV event and death. Plasma PCSK9 level was positively correlated with total cholesterol level in patients with statin treatment. Multivariate linear regression analysis revealed that baseline serum glucose, albumin, total cholesterol, and statin treatment were independent determinants of circulating PCSK9 levels. Cumulative rates of composite and CV events were significantly higher in patients with tertile 3 PCSK9 (p = 0.017 and p = 0.010, respectively). In multivariate Cox-regression analysis, PCSK9 tertile 3 was associated with a 1.97-fold risk of composite events (95% CI, 1.13–3.45), and it was associated with a 2.31-fold risk of CV events (95% CI, 1.17–4.59). In conclusion, a higher circulating PCSK9 level was independently associated with incident CV events and death in HD patients. These results suggest the importance of future studies regarding the effect of PCSK9 inhibition. MDPI 2020-01-17 /pmc/articles/PMC7019341/ /pubmed/31963408 http://dx.doi.org/10.3390/jcm9010244 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hwang, Hyeon Seok Kim, Jin Sug Kim, Yang Gyun Lee, So-Young Ahn, Shin Young Lee, Hong Joo Lee, Dong-Young Lee, Sang Ho Moon, Ju Young Jeong, Kyung Hwan Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients |
title | Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients |
title_full | Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients |
title_fullStr | Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients |
title_full_unstemmed | Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients |
title_short | Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients |
title_sort | circulating pcsk9 level and risk of cardiovascular events and death in hemodialysis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019341/ https://www.ncbi.nlm.nih.gov/pubmed/31963408 http://dx.doi.org/10.3390/jcm9010244 |
work_keys_str_mv | AT hwanghyeonseok circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT kimjinsug circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT kimyanggyun circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT leesoyoung circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT ahnshinyoung circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT leehongjoo circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT leedongyoung circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT leesangho circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT moonjuyoung circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients AT jeongkyunghwan circulatingpcsk9levelandriskofcardiovasculareventsanddeathinhemodialysispatients |